Cue Biopharma (CUE) Total Current Liabilities (2017 - 2025)

Cue Biopharma has reported Total Current Liabilities for 9 years, with the latest figure at $13.5 million in Q4 2025.

• Quarterly Total Current Liabilities fell 1.42% year-over-year to $13.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $13.5 million (down 1.42% YoY) and the FY2025 annual result came in at $13.5 million, down 1.42% from the prior year.
• Total Current Liabilities eased to $13.5 million in Q4 2025 per CUE's latest filing, from $15.5 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $19.3 million in Q2 2025 and troughed at $8.3 million in Q2 2022.
• A 5-year average of $14.8 million and a median of $15.5 million in 2025 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities plunged 50.08% in 2022, then surged 95.93% in 2023.
• Over 5 years, Total Current Liabilities stood at $12.8 million in 2021, then retreated by 9.69% to $11.5 million in 2022, then soared by 47.91% to $17.1 million in 2023, then decreased by 19.86% to $13.7 million in 2024, then decreased by 1.42% to $13.5 million in 2025.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $13.5 million, $15.5 million, and $19.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.